| V oL U M E 3 3 | N U M B Er 2 | A p r iL 2 0 1 0 w w w. a u s t ra l i a n p re s c riber.com Summary rivaroxaban and dabigatran etexilate are oral anticoagulants that promise to be as effective as warfarin, but easier to use. The new drugs have shown similar or greater efficacy than low molecular weight heparins and comparable safety in the prevention of venous thromboembolism after hip or knee arthroplasty. Unlike other anticoagulants, routine monitoring is not required during short-term use. The drugs are also being assessed for other indications that include treatment of venous thromboembolism and preventing stroke in atrial fibrillation. only the results of ongoing studies will tell if they can match warfarin and the heparins across their full range of clinical indications.
introduction
The two widely used classes of anticoagulant are the heparins, and the vitamin K antagonists such as warfarin. Heparins are best suited for short-term prevention and initial treatment of venous thromboembolism or arterial occlusion, but can be given long-term. Warfarin is the mainstay of long-term therapy and is also used for atrial fibrillation and patients with mechanical heart valves. These drugs are highly effective, but have well-known limitations in addition to the risk of bleeding.
Heparins require injection or infusion. Warfarin has a narrow therapeutic window, variable dose response and multiple interactions with other drugs and concurrent illnesses, and there is a need for frequent laboratory monitoring of doseeffect.
Rivaroxaban and dabigatran etexilate are new oral anticoagulants which should be simpler to use than heparins or warfarin. 1, 2 They have predictable oral bioavailability and pharmacokinetics, few drug interactions and are suitable for daily dosing. 3, 4 one dose regimen should suit most patients regardless of body weight, age and gender without the need for laboratory monitoring.
preventing venous thromboembolism after major joint surgery
As the Australian population ages there will be increasing demand for elective hip or knee replacement and surgery after hip fracture. As these procedures are often complicated by thromboembolism, clinical practice guidelines recommend effective anticoagulant prophylaxis for at least ten days after surgery. 5 enoxaparin is the most widely used low molecular weight heparin. In Australia and europe 40 mg is given daily, whereas in North America the dose is 30 mg 12-hourly. Despite prophylaxis, about 2.5% of patients develop symptomatic deep vein thrombosis or pulmonary embolism during the three months after major joint surgery. About two-thirds of cases occur after discharge from hospital. 6, 7 In clinical trials subclinical deep vein thrombosis is found despite effective prophylaxis in up to 30% of patients when screening venography is done 7-10 days after surgery. The rate of clinical thromboembolism after hip replacement is reduced when prophylaxis is continued for 4-5 weeks after discharge. Selected patients who have an ongoing risk of experimental and clinical pharmacology 
New oral anticoagulants -clinical applications

Efficacy versus bleeding risk
Surgeons are wary of surgical bleeding after joint replacement, since wound haematoma delays recovery and may predispose to infections that can endanger the prosthesis. This adds importance to evidence regarding the balance of efficacy and risk of bleeding with the new anticoagulants.
In clinical trials the efficacy of the new drugs was assessed by the incidence of total, major and clinical venous thromboembolism (see box). The primary measure of efficacy was the incidence of 'total venous thromboembolism'. A reduction in this composite end point has been accepted by government regulators and most guideline development groups as indicating efficacy. However, others argue that a composite of proximal vein thrombosis with clinical thromboembolism or even symptomatic pulmonary embolism alone should be the main measure. This debate is unfinished. 8 Bleeding was reported as 'major' or 'clinically relevant but non-major'. The studies also reported bleeding from the wound, but this was not always considered as major bleeding if re-operation was not needed. Rates refer to events during or soon after study treatment Rivaroxaban dose was 10 mg once daily, starting 6-8 hours after wound closure. In ReCoRD 1, 2 and 3, enoxaparin 40 mg was given 12 hours before surgery and then daily from 6-8 hours after wound closure. enoxaparin dose in ReCoRD4 was 30 mg twice daily, starting 12-24 hours after surgery.
rivaroxaban
This orally active factor Xa inhibitor was compared with enoxaparin in four double-blind randomised trials for the prevention of venous thromboembolism. These were ReCoRD1 and ReCoRD2 for total hip replacement, 9, 10 and ReCoRD3 and ReCoRD4 for total knee replacement 11, 12 ( Efficacy (Table 1) Rivaroxaban was more effective than enoxaparin in and all-cause mortality was reduced from 0.8% to 0.4% by rivaroxaban (p = 0.005). 13
Bleeding (Table 1) The rates of major or clinically relevant non-major bleeding were similar with rivaroxaban and enoxaparin 40 mg once daily. The apparent increases in bleeding were small and statistically insignificant. An overview found that rates of wound infection and re-operation due to bleeding were low and comparable. 13 The near absence of 'major' bleeding is explained in part by a study definition which excluded woundrelated bleeding unless it was fatal or led to re-operation.
dabigatran etexilate
This orally active thrombin inhibitor has been compared with enoxaparin in three double-blind randomised trials (Table 2) . one trial was in hip replacement (Re-NoVATe) 14 and two were in knee replacement (Re-MoDeL and Re-MoBILIZe). 15, 16 All compared two doses of dabigatran (220 mg once daily and 150 mg once daily) with enoxaparin.
Treatment continued for 28-35 days in Re-NoVATe, 6-10 days in Re-MoDeL, and 12-15 days in Re-MoBILIZe.
The studies most relevant to Australia are Re-NoVATe and
Re-MoDeL as dabigatran was given as a half-dose 1-4 hours after surgery, and 40 mg once-daily enoxaparin was started on the evening before surgery. In Re-MoBILIZe the initial half-dose of dabigatran was given 6-12 hours after surgery and 30 mg enoxaparin 12-hourly was started 12-24 hours after surgery.
Efficacy (Table 2)
Both doses of dabigatran were statistically 'non-inferior' to enoxaparin in Re-NoVATe and Re-MoDeL. In Re-MoBILIZe the total rates of venous thromboembolism with the two dabigatran regimens were significantly higher than with twice-daily enoxaparin.
Bleeding (Table 2) The rates of major or clinically relevant non-major bleeding were similar with the two dabigatran regimens and with enoxaparin. An overview showed a slight excess of bleeding with dabigatran 220 mg once daily, compared with enoxaparin 40 mg once daily, but this was not statistically significant. 17
response to bleeding
Rivaroxaban and dabigatran etexilate have no antidote.
Circulating half-lives of 9-13 hours (rivaroxaban) and 
Spinal or epidural anaesthesia
over two-thirds of patients in these studies had surgery under regional (spinal or epidural) anaesthesia with or without a general anaesthetic, but study protocols required epidural anaesthesia to cease before the first (postoperative) dose of oral anticoagulant.
How do the new drugs compare with each other?
There are well-known limitations to any use of results from separate clinical trial programs to estimate relative efficacy of different drugs. Nevertheless, for rivaroxaban and dabigatran, in these large studies the demographics of study populations appear similar, as were study inclusion and exclusion criteria, so results should be broadly comparable -provided comparisons are of relative and not absolute outcome rates. Dabigatran doses were 220 mg once daily and 150 mg once daily, beginning after surgery with a half-dose. In Re-NoVATe and Re-MoDeL, the half-dose was given 1-4 hours after surgery and the enoxaparin dose was 40 mg once daily starting on the evening before surgery. In Re-MoBILIZe, the half-dose was given 6-12 hours after surgery and 12-hourly enoxaparin 30 mg was started 12-24 hours after surgery. A new drug is considered 'non-inferior' (no less effective) than standard therapy if study outcomes meet predefined statistical targets, as in Re-NoVATe and Re-MoDeL.
With that proviso, the results with rivaroxaban appear more impressive, since 10 mg once daily started 6-8 hours after surgery was superior to enoxaparin 40 mg once daily for several outcomes with a similar risk of bleeding. 
